NYSE:CMD

Cantel Medical Competitors

$83.76
+0.38 (+0.46 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$83.02
Now: $83.76
$83.99
50-Day Range
$73.00
MA: $77.56
$83.38
52-Week Range
$26.19
Now: $83.76
$89.10
Volume337,329 shs
Average Volume566,112 shs
Market Capitalization$3.54 billion
P/E Ratio99.72
Dividend YieldN/A
Beta1.54

Competitors

Cantel Medical (NYSE:CMD) Vs. NVCR, PEN, HRC, GMED, HAE, and INSP

Should you be buying CMD stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Cantel Medical, including NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), and Inspire Medical Systems (INSP).

NovoCure (NASDAQ:NVCR) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NovoCure and Cantel Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
Cantel Medical12102.00

NovoCure presently has a consensus price target of $139.2857, suggesting a potential upside of 5.45%. Cantel Medical has a consensus price target of $71.50, suggesting a potential downside of 14.64%. Given NovoCure's stronger consensus rating and higher probable upside, research analysts plainly believe NovoCure is more favorable than Cantel Medical.

Earnings & Valuation

This table compares NovoCure and Cantel Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million38.51$-7,230,000.00($0.07)-1,887.00
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76

Cantel Medical has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NovoCure and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
Cantel Medical3.38%11.19%4.10%

Volatility & Risk

NovoCure has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

Institutional & Insider Ownership

71.1% of NovoCure shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 5.1% of NovoCure shares are held by company insiders. Comparatively, 10.7% of Cantel Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cantel Medical beats NovoCure on 8 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cantel Medical and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical12102.00
Penumbra02402.67

Cantel Medical currently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Penumbra has a consensus price target of $279.00, indicating a potential upside of 2.56%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Cantel Medical.

Earnings & Valuation

This table compares Cantel Medical and Penumbra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76
Penumbra$547.41 million18.11$48.46 million$0.98277.58

Penumbra has lower revenue, but higher earnings than Cantel Medical. Cantel Medical is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cantel Medical and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical3.38%11.19%4.10%
Penumbra-1.79%-0.12%-0.09%

Risk and Volatility

Cantel Medical has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Cantel Medical beats Penumbra on 9 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Cantel Medical (NYSE:CMD) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Hill-Rom and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.74%22.71%8.01%
Cantel Medical3.38%11.19%4.10%

Institutional and Insider Ownership

83.8% of Hill-Rom shares are owned by institutional investors. Comparatively, 95.0% of Cantel Medical shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by company insiders. Comparatively, 10.7% of Cantel Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Hill-Rom and Cantel Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.88 billion2.60$223 million$5.5320.42
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76

Hill-Rom has higher revenue and earnings than Cantel Medical. Hill-Rom is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hill-Rom and Cantel Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
Cantel Medical12102.00

Hill-Rom presently has a consensus price target of $121.00, indicating a potential upside of 7.14%. Cantel Medical has a consensus price target of $71.50, indicating a potential downside of 14.64%. Given Hill-Rom's stronger consensus rating and higher probable upside, research analysts clearly believe Hill-Rom is more favorable than Cantel Medical.

Volatility & Risk

Hill-Rom has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Summary

Hill-Rom beats Cantel Medical on 9 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

95.0% of Cantel Medical shares are held by institutional investors. Comparatively, 64.4% of Globus Medical shares are held by institutional investors. 10.7% of Cantel Medical shares are held by insiders. Comparatively, 25.6% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cantel Medical and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical3.38%11.19%4.10%
Globus Medical12.36%9.85%9.04%

Valuation & Earnings

This table compares Cantel Medical and Globus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76
Globus Medical$785.37 million8.51$155.21 million$1.6839.88

Globus Medical has lower revenue, but higher earnings than Cantel Medical. Globus Medical is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cantel Medical has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cantel Medical and Globus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical12102.00
Globus Medical041002.71

Cantel Medical presently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Globus Medical has a consensus price target of $66.40, indicating a potential downside of 0.90%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than Cantel Medical.

Summary

Globus Medical beats Cantel Medical on 9 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Cantel Medical (NYSE:CMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares Haemonetics and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Cantel Medical3.38%11.19%4.10%

Risk and Volatility

Haemonetics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Haemonetics and Cantel Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
Cantel Medical12102.00

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 23.70%. Cantel Medical has a consensus price target of $71.50, suggesting a potential downside of 14.64%. Given Haemonetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Haemonetics is more favorable than Cantel Medical.

Valuation & Earnings

This table compares Haemonetics and Cantel Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.02$76.53 million$3.3135.37
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76

Haemonetics has higher earnings, but lower revenue than Cantel Medical. Haemonetics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.2% of Haemonetics shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 1.6% of Haemonetics shares are held by insiders. Comparatively, 10.7% of Cantel Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Haemonetics beats Cantel Medical on 10 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Inspire Medical Systems (NYSE:INSP) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

95.0% of Cantel Medical shares are held by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are held by institutional investors. 10.7% of Cantel Medical shares are held by company insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cantel Medical and Inspire Medical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04

Cantel Medical has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Cantel Medical and Inspire Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical12102.00
Inspire Medical Systems03802.73

Cantel Medical currently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Inspire Medical Systems has a consensus price target of $168.5455, indicating a potential downside of 22.84%. Given Cantel Medical's higher probable upside, equities analysts plainly believe Cantel Medical is more favorable than Inspire Medical Systems.

Volatility and Risk

Cantel Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Profitability

This table compares Cantel Medical and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical3.38%11.19%4.10%
Inspire Medical Systems-61.07%-32.23%-26.42%

Summary

Cantel Medical beats Inspire Medical Systems on 9 of the 14 factors compared between the two stocks.


Cantel Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NovoCure logo
NVCR
NovoCure
1.5$132.09+0.3%$13.53 billion$351.32 million695.25Analyst Upgrade
Insider Selling
Penumbra logo
PEN
Penumbra
1.5$272.03+0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94+1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00+1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55Gap Up
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$218.45+3.3%$5.93 billion$82.05 million-94.16Gap Up
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12+0.9%$5.92 billion$1.52 billion104.66
Inari Medical logo
NARI
Inari Medical
1.1$113.64+0.2%$5.54 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99+0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08+0.9%$5.09 billion$390.26 million-54.07
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$137.01+0.7%$4.77 billion$42.93 million-67.83
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76+1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13+3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
NuVasive logo
NUVA
NuVasive
1.1$68.71+1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90+1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13+0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
High Trading Volume
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07+0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50+3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
Soliton logo
SOLY
Soliton
1.1$18.25+0.1%$386.90 millionN/A-24.33
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.